Simplex Trading
BCLI

Simplex Trading’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Simplex Trading’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-360
Closed -$1K – 8501
2024
Q3 		$1K Hold
360
– – ﹤0.01% 8133
2024
Q2 		$1K Buy
360
+220
+157% +$1.65K ﹤0.01% 8417
2024
Q1 		$1K Buy
+140
New +$770 ﹤0.01% 8525
2023
Q4 		– Sell
-6,713
Closed -$20K – 8760
2023
Q3 		$20K Buy
6,713
+3,513
+110% +$79.9K ﹤0.01% 6605
2023
Q2 		$98K Buy
3,200
+2,153
+206% +$89.2K ﹤0.01% 5096
2023
Q1 		$51K Buy
1,047
+420
+67% +$12.2K ﹤0.01% 5894
2022
Q4 		$15K Sell
627
-333
-35% -$12.4K ﹤0.01% 7125
2022
Q3 		$63K Buy
960
+753
+364% +$37.8K ﹤0.01% 6110
2022
Q2 		$8K Sell
207
-280
-57% -$12.6K ﹤0.01% 8439
2022
Q1 		$24K Sell
487
-3,740
-88% -$184K ﹤0.01% 8020
2021
Q4 		$253K Sell
4,227
-1,746
-29% -$85.9K ﹤0.01% 4826
2021
Q3 		$339K Hold
5,973
– – ﹤0.01% 4702
2021
Q2 		$340K Buy
5,973
+5,898
+7,864% +$315K ﹤0.01% 4762
2021
Q1 		$428K Buy
75
+44
+142% +$3.32K ﹤0.01% 3597
2020
Q4 		$213K Buy
31
+17
+121% +$2.31K ﹤0.01% 4512
2020
Q3 		$346K Buy
14
+4
+40% +$819 ﹤0.01% 3442
2020
Q2 		$174K Sell
10
-22
-69% -$2.37K ﹤0.01% 4146
2020
Q1 		$220K Buy
+32
New +$2.5K ﹤0.01% 3481
2019
Q4 		– Sell
-10
Closed -$60K – 7274
2019
Q3 		$60K Sell
10
-3
-23% -$177 ﹤0.01% 4832
2019
Q2 		$78K Sell
13
-1
-7% -$58 ﹤0.01% 4441
2019
Q1 		$89K Buy
+14
New +$796 ﹤0.01% 4467
2018
Q1 		– Sell
-1
Closed -$1K – 6122
2017
Q4 		$1K Hold
1
– – ﹤0.01% 5426
2017
Q3 		$1K Buy
+1
New +$65 ﹤0.01% 5345
2017
Q2 		– Sell
-1
Closed -$1K – 6083
2017
Q1 		$1K Sell
1
-3
-75% -$156 ﹤0.01% 5552
2016
Q4 		$2K Buy
+4
New +$139 ﹤0.01% 4980

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading's BCLI Position: Q4 2024 in Review

Simplex Trading sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 77 shares.

Simplex Trading first reported a position in BCLI in Q3 2015 and held it in 25 quarters. The position peaked at $605K in Q1 2023. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • Simplex Trading reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • Simplex Trading sold 77 BRAINSTORM CELL THERAPUTC shares in Q4 2024.
  • Simplex Trading first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2015 and held it in 25 quarters.
  • Simplex Trading's BRAINSTORM CELL THERAPUTC position peaked at $605K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on Simplex Trading's 13F filing for Q4 2024, filed 11 Feb 2025.